melanoma | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
BRIM 8, 2018 | vemurafenib vs placebo | PFS 0.65 [0.50; 0.85] | | OS 0.72 [0.49; 1.08] | BRIM 8 (cohort IIIC) | vemurafenib vs placebo | | | PFS 0.80 [0.54; 1.18] RFS 0.80 [0.54; 1.18] DMFS 0.91 [0.57; 1.45] |
Trial | Treatments | Patients | Method |
---|
BRIM 8, 2018 | e twice-daily adjuvant oral vemurafenib 960 mg tablets for52 weeks (13×28-day cycles) (n=-9) vs. placebo (n=-9) | patients with resected,BRAFV600 mutation-positive melanoma: IC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2) | Sample size: -9/-9 Primary endpoint: FU duration: | BRIM 8 (cohort IIIC) | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|